Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2013 Nov 8;19:357-64. doi: 10.2119/molmed.2013.00140. Erratum in: Mol Med. 2014;20():37. Corrected and republished in: Mol Med. 2014;20:29-36.

2.

CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2014 Mar 14;20:29-36. doi: 10.2119/molmed.2013.00140.revised.

3.

Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease.

Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, Cheng D, Karl T, Garner B.

J Neurosci. 2013 Mar 6;33(10):4387-94. doi: 10.1523/JNEUROSCI.4165-12.2013.

4.

Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.

J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008.

5.
6.

Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network.

Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, Strittmatter SM; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2017 May;133(5):785-807. doi: 10.1007/s00401-017-1668-z. Epub 2017 Jan 9.

PMID:
28070672
7.

Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.

Aso E, Andrés-Benito P, Carmona M, Maldonado R, Ferrer I.

J Alzheimers Dis. 2016;51(2):489-500. doi: 10.3233/JAD-150913.

PMID:
26890764
8.

Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model.

Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S.

Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20816-21. doi: 10.1073/pnas.1005888107. Epub 2010 Nov 12.

9.

Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease.

Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B.

PLoS One. 2013;8(4):e59586. doi: 10.1371/journal.pone.0059586. Epub 2013 Apr 1.

10.

Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T.

Glia. 2010 Feb;58(3):300-14. doi: 10.1002/glia.20924.

11.

The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.

Collins JM, King AE, Woodhouse A, Kirkcaldie MT, Vickers JC.

Exp Neurol. 2015 May;267:219-29. doi: 10.1016/j.expneurol.2015.02.034. Epub 2015 Mar 4.

PMID:
25747037
12.

Central vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's disease.

Ramos-Rodriguez JJ, Jimenez-Palomares M, Murillo-Carretero MI, Infante-Garcia C, Berrocoso E, Hernandez-Pacho F, Lechuga-Sancho AM, Cozar-Castellano I, Garcia-Alloza M.

Psychoneuroendocrinology. 2015 Dec;62:69-79. doi: 10.1016/j.psyneuen.2015.07.606. Epub 2015 Jul 26.

PMID:
26254770
13.

Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.

Ji B, Maeda J, Sawada M, Ono M, Okauchi T, Inaji M, Zhang MR, Suzuki K, Ando K, Staufenbiel M, Trojanowski JQ, Lee VM, Higuchi M, Suhara T.

J Neurosci. 2008 Nov 19;28(47):12255-67. doi: 10.1523/JNEUROSCI.2312-08.2008.

14.

Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model.

Katsouri L, Georgopoulos S.

PLoS One. 2011;6(7):e21880. doi: 10.1371/journal.pone.0021880. Epub 2011 Jul 6.

15.

Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.

Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I.

J Neurosci. 2010 Jul 7;30(27):9228-40. doi: 10.1523/JNEUROSCI.0418-10.2010.

16.

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.

Natunen T, Takalo M, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KMA, Pursiheimo JP, Sarajärvi T, Viswanathan J, Gabbouj S, Solje E, Tahvanainen E, Pirttimäki T, Kurki M, Paananen J, Rauramaa T, Miettinen P, Mäkinen P, Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A, Hiltunen M.

Neurobiol Dis. 2016 Jan;85:187-205. doi: 10.1016/j.nbd.2015.11.005. Epub 2015 Nov 10.

PMID:
26563932
17.

Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation.

Savonenko AV, Melnikova T, Wang Y, Ravert H, Gao Y, Koppel J, Lee D, Pletnikova O, Cho E, Sayyida N, Hiatt A, Troncoso J, Davies P, Dannals RF, Pomper MG, Horti AG.

PLoS One. 2015 Jun 18;10(6):e0129618. doi: 10.1371/journal.pone.0129618. eCollection 2015.

18.

Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.

Guo Q, Li H, Cole AL, Hur JY, Li Y, Zheng H.

PLoS One. 2013 Nov 20;8(11):e80706. doi: 10.1371/journal.pone.0080706. eCollection 2013.

19.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674
20.

APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.

Barbero-Camps E, Fernández A, Martínez L, Fernández-Checa JC, Colell A.

Hum Mol Genet. 2013 Sep 1;22(17):3460-76. doi: 10.1093/hmg/ddt201. Epub 2013 May 6.

Supplemental Content

Support Center